Yulia Slavina

AI reformulates synthetic POCs bypassing screening, Twist Bioscience warns

AI reformulates synthetic POCs bypassing screening, Twist Bioscience warns
AI exposes biosecurity software gaps

Twist Bioscience reports that AI engineering has enabled the creation of synthetic homologs of potentially dangerous biological sequences which can evade existing biosecurity screening systems by fragmenting them into smaller oligo segments.

Bruce Wittmann, Microsoft Research technical fellow Eric Horvitz, and James Diggans of Twist Bioscience, along with their teams, conducted a detailed examination of these vulnerabilities, highlighting how advances in artificial intelligence could challenge the efficacy of biosecurity oversight tools.

The rapid evolution of artificial intelligence in synthetic biology not only poses new challenges for biosecurity frameworks but also builds upon Twist Bioscience's broader advances in the field. The company's prior work in developing engineered immune cells to target type 1 diabetes demonstrates its dual focus on both leveraging and safeguarding biotechnology’s potential, as seen in its approach to novel solutions for disease treatment.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.